Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04982991 | Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants | PHASE1 | COMPLETED | 14 | — | — | Aug 5, 2021 | Oct 11, 2021 | Apr 25, 2022 | 1 | United Kingdom |
Maximum plasma concentration
Area under the plasma concentration versus time curve from time zero to the real time last
Area under the plasma concentration versus time curve
| Arm | Type | Description |
|---|---|---|
| SAR443820 | EXPERIMENTAL | Participants will receive a single sequence of 3 different doses of SAR443820 in a total of 3 treatment periods |
| Name | Type | Description |
|---|---|---|
| RIPK1 inhibitor | DRUG | Capsule Oral |
Inclusion Criteria: East Asian (Chinese and Japanese) male and/or female participant must be 20 to 55 years of age inclusive, at the time of signing the informed consent. Chinese or Japanese ethnicity, according to the following criteria: Chinese; born in China or ethnic Chinese born outside of C...